Alnylam Pharmaceuticals, Inc.'s Pipeline Progresses, Approval Next
Even though biotech Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't have any drugs on the market, it had a solid third quarter in terms of pipeline development, with a drug passing its phase 3 trial, joining two others that are already in phase 3 development.
Metric
Q3 2017
Source: Fool.com
Alnylam Pharmace. Stock
€234.40
-9.600%
The stock is an absolute favorite of our community with 46 Buy predictions and no Sell predictions.
As a result the target price of 271 € shows a slightly positive potential of 15.61% compared to the current price of 234.4 € for Alnylam Pharmace..
